ClinicalTrials.gg
RecruitingNCT05866029Updated Jan 12, 2026

Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

An interventional study of Denosumab and Teriparatide in Osteoporotic Fractures, sponsored by Peking Union Medical College Hospital. Recruiting at 58 sites in China. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,478
Allocation
Randomized
Ages
45 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoporotic Fractures with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Osteoporotic Fractures · China.

Started
2023
with 1 other
No phase
5 of 13
3 open now
Registered
9th of 13
by date
Lead sponsor
3 of 13
Peking Union Medical College Hospital

Among the 13 studies in Osteoporotic Fractures with a site in China, this one is one of 2 that started in 2023, is one of 5 with no phase, and was the 9th registered.

Osteoporotic Fractures

87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.

Browse Osteoporotic Fractures studies →

Open to participants now

7 of the 13 studies in Osteoporotic Fractures with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 14 Osteoporotic Fractures studies recruiting now, 9 (64%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 45 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoporotic Fractures with a site in China, or all of them as a file.
02

Study summary

This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies. By registering for follow-up studies on osteoporotic fractures, it is planned to obtain epidemiological data through registration and follow-up studies; A prospective treatment study for patients with osteoporotic fractures is planned to explore effective treatment strategies through randomized controlled trials; To study biomarkers for osteoporotic refractures, we plan to establish a biomarker warning model through multi omics research; To study imaging biomarkers for osteoporotic refractures, a new imaging technology is proposed to establish an imaging omics warning model.

03

Conditions studied

  • Osteoporotic Fractures

Keywords

  • osteoporosis
  • osteoporotic fractures
  • bone turnover markers
  • imaging biomarkers
04

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. New brittle hip fractures;
  2. New brittle vertebral fractures;
  3. New other site fractures and/or total hip or neck of femur or L1-L4 T-value \< -1.0;
  4. Men or women;
  5. Age 45-90 years old;
  6. Ability to move autonomously

Exclusion criteria

Exclusion Criteria:

  1. bone metabolic diseases except for osteoporosis eg. a. (Osteogenesis Imperfecta, Paget's disease, Osteomalacia), b. Cushing's syndrome, c.hyperprolactinemia;
  2. Having primary hyperparathyroidism or hypothyroidism;
  3. Had or have osteomyelitis of the jaw or necrosis of the jaw;
  4. \<30ml/min/1.73m2;
  5. Active infection that requires systematic treatment;
  6. Used intravenous bisphosphonate, fluoride, or strontium for osteoporosis within 2 years;
  7. Used teriparatide and denosumab for osteoporosis within 6 months;
  8. Used (equivalent to >5 mg/day prednisone) for more than 10 days within 6 weeks;
  9. The time gap between the first time and the last time oral bisphosphonate for osteoporosis less than 1 year( if used within one year, but the cumulative use is ≤ 1 month, the subject can be enrolled) ;
  10. Patients with malignant tumors or bone within 5 years, except tumors that are expected to be cured after treatment;
  11. Have hypocalcemia and hypercalcemia;
  12. Unexplained elevation of alkaline phosphatase;
  13. A serious deficiency of vitamin D (25OHD \<10ng/mL);
  14. Patients who have previously received external radiation or radiation therapy with bone implants;
  15. Uncontrolled comorbidities included heart failure above the New York cardiac Function Scale, glycosylated > 8.5%, and severe arrhythmias;
  16. Planned pregnancy and lactation at present or during the study period;
  17. Allergic to teriparatide and denosumab;
  18. Participating in clinical trials of other drugs at present;
  19. subjects do not suitable for this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2,478 participants (estimated)

Study arms

  • Active comparator
    60mg of Denosumab treatment

    Monotherapy with denosumab injection ( 60mg, subcutaneous injection, semi-annually) for 24 months.

    Drug: Denosumab

  • Experimental
    Teriparatide was sequentially treated with Denosumab

    1. Treatment with teriparatide injection ( 20ug, subcutaneous injection, once daily) for 6 months, followed by discontinuation of teriparatide and change to denosumab injection ( 60mg, subcutaneous injection, once every six months) and continued until the 24th month. 2. Treatment with teriparatide injection ( 20ug, subcutaneous injection, once daily) for 12 months, followed by discontinuation of teriparatide and change to denosumab injection ( 60mg, subcutaneous injection, semi-annually) treatment continued until the 24th month.

    Drug: Denosumab · Drug: Teriparatide

Interventions

  • Active Comparator: 60mg of Denosumab treatment by subcutaneous injection

  • Teriparatide was sequentially treated with Denosumab

06

What researchers measure

Primary outcomes

  1. The main study:The incidence of new vertebral fractures

    The main study:the incidence of new vertebral fractures (clinical and imaging) within 24 months of treatment

    Time frame: Within 24 months of treatment

  2. The sub study:The rate of change in BMD from baseline at lumbar spine in 24 months

    Time frame: Within 24 months of treatment

Secondary outcomes

  1. The main study:New vertebral fractures in 12 months

    Time frame: Within 12 months of treatment

  2. The main study:New hip fractures, new fractures at other sites, and all new fractures at 12 and 24 months

    Time frame: Within 12 months and 24 months of treatment

  3. The main study:The rate of BMD change from the baseline at the lumbar spine, total hip, and femoral neck in 12 and 24 months;

    Time frame: Within 12 months and 24 months of treatment

  4. The main study:The rate of changes from baseline in serum type 1 collagen cross-linked C-terminal peptide (β-CTX) and type 1 procollagen N-terminal propeptide (P1NP) at 6, 12, and 24 months

    Time frame: 6, 12, and 24 months

  5. The main study:The patients' adherence to treatment

    Non-adherence rate=Number of patients non-adherencet with teriparatide or denosumab / Total number of patients. 1. Denosumab Adherence Adherence to denosumab treatment was assessed based on protocol compliance during the study period. Non-adherence was defined as one or more instances in which the scheduled denosumab injection was not administered according to the study protocol, including doses received outside the permissible treatment window (±4 weeks). 2. Teriparatide Adherence Adherence to teriparatide was evaluated only in the two sequential treatment groups assigned to receive teriparatide. Using patient diary records, non-adherence was defined as an actual-to-expected injection day ratio of less than 80% or greater than 120% over the course of the study period.

    Time frame: 24 months

  6. The main study:Cost-effectiveness

    The incremental cost-effectiveness ratio is defined as the average additional drug cost required per additional fracture event avoided in the intervention group compared to the control group.

    Time frame: 24 months

  7. The sub study:BMD change at lumbar spine in 12 months

    Time frame: Within 12 months of treatment

  8. The sub study:BMD changes at total hip and femoral neck in 12 and 24 months

    Time frame: Within 12 months and 24 months of treatment

  9. The sub study:Serum β-CTX and P1NP levels at 12 and 24 months

    Time frame: 12 months and 24 months

  10. The sub study:The incidence of new vertebral fractures, hip fractures, new fractures at other sites, and all new fractures in 12 and 24 months

    Time frame: Within 12 months and 24 months of treatment

07

Study locations

58 of 58 sites recruiting
08

References and documents

Publications

  • Chi Y, Zhu Y, Yuan J, Pang Q, Cui L, Jiang Y, Jiajue R, Liu W, Wang O, Li M, Xing X, Li H, Xie G, Wu Y, Xia W. Efficacy of sequential denosumab after teriparatide for 6 months compared with denosumab monotherapy in reducing risk of osteoporotic fractures in patients with new fractures: a multicentre randomised controlled trial (STAND study) protocol. BMJ Open. 2026 Feb 26;16(2):e111364. doi: 10.1136/bmjopen-2025-111364. PubMed 41748193 ↗

Individual participant data

Plan to share: Yes — Data related to this study will be made available upon reasonable request.

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Sep 2026, 40 months after the start.

Of 22 interventional studies with no phase under Osteoporotic Fractures, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 19, 2023
StartActual
May 26, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05866029
Responsible party
Sponsor
First posted
May 19, 2023
Start date
May 26, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Weibo Xia
Contact
xiaweibo8301@163.com
13501002126
Weibo Xia, MD.
study chair · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teriparatide

Start the discussion